Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06081517 · ClinicalTrials.gov registry record
Evaluating Disparities in Precision Oncology
A clinical trial of Advanced Cancer and Metastatic Cancer, sponsored by Indiana University.
- Recruiting
- Registry status
- 10,600
- Enrollment target
- 1
- Study location
NCT06081517 is a study of Advanced Cancer and Metastatic Cancer that is actively recruiting participants, run by Indiana University. The registered enrollment target is 10,600 participants, above the 159-participant average among 122 other Advanced Cancer trials with a reported enrollment target (6567% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06081517, a study of Advanced Cancer and Metastatic Cancer, is actively recruiting participants, sponsored by Indiana University.
- RECRUITING
- Registry status
- 10,600 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.
Conditions Studied
Interventions
- BEHAVIORAL Social Determinants of Health and toxicity questionnaires
Study Locations (1)
Indiana
- Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,600 participants |
| Start Date | 2024-01-26 |
| Est. Completion | 2028-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06081517
The ClinicalTrials.gov registry entry for NCT06081517 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 10,600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 159-participant average among 122 other Advanced Cancer trials with a reported enrollment target (6567% higher). The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which Social Determinants of Health and toxicity questionnaires is the first listed.
NCT06081517 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT06081517 about?
NCT06081517 is a clinical study titled "Evaluating Disparities in Precision Oncology". This is a non-randomized observational trial designed to collect detailed clinical, social determinant, and genomic data from patients enrolled in molecular oncology tumor boards across four comprehensive cancer centers.
What is the current status of trial NCT06081517?
This trial is currently recruiting. The enrollment target is 10,600 participants. The study started on 2024-01-26. Estimated completion is 2028-12.
What conditions does trial NCT06081517 study?
This clinical trial studies the following conditions: Advanced Cancer, Metastatic Cancer.
What interventions are being tested in trial NCT06081517?
The interventions under investigation include: Social Determinants of Health and toxicity questionnaires (BEHAVIORAL).
Who is sponsoring clinical trial NCT06081517?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06081517 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BOLSTER: Learning New Skills to Thrive
RECRUITING · NA
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Longitudinal Screening for Financial Hardship to Improve Outcomes in Patients With Advanced Cancer
RECRUITING · NA
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Pilot Trial of Spiritual Care Interventions for Patients With Cancer
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.